Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (686)	12/2/1998 7:06:00 AM
From: LFQ	Read Replies (4) \| Respond to of 2539

Anthony, thanks for your posts. Although I have not seen the data from Searle, it looks like the incidence (occurence) of gastric bleeding requiring hospitalization from the study were so low that: either the difference between the placebo and control group is not statistically significant for this event (gastric bleeding requiring hospitalization) or the low numbers do not permit them to draw statistical conclusion. LFQ

To: Anthony Wong who wrote (686)	12/2/1998 9:35:00 AM
From: chirodoc	Read Replies (2) \| Respond to of 2539

there is a difference between a full blown bleeding ulcer and a small ulceration panel is saying, yes there were ulcers in the nsaid group yes, there were less ulcers in the celebrex group but maybe those ulcers weren't that serious and they would have healed on their own meaning celebrex isn't that great real issue is with long term use where they could become more serious so short term they are saying nsaids may be no more dangerous than celebrex is that helpful? curtis